Systematic Reviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Apr 19, 2024; 14(4): 582-599
Published online Apr 19, 2024. doi: 10.5498/wjp.v14.i4.582
Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review
Ana V Pejčić, Srdjan M Stefanović, Miloš N Milosavljević, Vladimir S Janjić, Marko M Folić, Nevena D Folić, Jovana Z Milosavljević
Ana V Pejčić, Miloš N Milosavljević, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Srdjan M Stefanović, Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Srdjan M Stefanović, Marko M Folić, Department of Clinical Pharmacology, University Clinical Center Kragujevac, Kragujevac 34000, Serbia
Vladimir S Janjić, Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Vladimir S Janjić, Clinic for Psychiatry, University Clinical Center Kragujevac, Kragujevac 34000, Serbia
Marko M Folić, Center for Pharmaceutical and Pharmacological Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Nevena D Folić, Department of Pediatrics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Nevena D Folić, Pediatric Clinic, University Clinical Center Kragujevac, Kragujevac 34000, Serbia
Jovana Z Milosavljević, Department of Anatomy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Author contributions: Pejčić AV, Stefanović SM, Milosavljević MN, Janjić VS, Folić MM, Folić ND, and Milosavljević JZ contributed to conception, design, literature search, data analysis, drafting and editing of the manuscript, and approved the final manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ana V Pejčić, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com
Received: December 3, 2023
Peer-review started: December 3, 2023
First decision: January 23, 2024
Revised: February 5, 2024
Accepted: March 6, 2024
Article in press: March 6, 2024
Published online: April 19, 2024
Processing time: 135 Days and 8.3 Hours
Core Tip

Core Tip: Considering that the currently available research on the use of long-acting injectable antipsychotics in pregnancy consists only of case reports and series, additional well-designed studies are needed to properly evaluate the risks and benefits of their use during pregnancy. Currently available data seem reassuring, given that most of the women seemed to have satisfactory control of the symptoms and that a minority of the cases reported adverse outcomes, such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns, while there were no reported negative long-term developmental outcomes.